

# Medical Imaging

## Experience from the Past 10 Years and State-of-the-Art

ENVISION General Meeting  
Stockholm  
Sept. 5, 2010

Wolfgang Enghardt  
OncoRay – Center for Radiation Research in Oncology  
Technische Universität Dresden, Germany  
and  
Forschungszentrum Dresden-Rossendorf, Dresden, Germany  
Institute of Radiation Physics



# Outline


---

1. Imaging for hadron therapy quality assurance
2. Lessons learned from particle therapy PET
3. Towards a real-time in-vivo dosimetry



# 1. Imaging for hadron therapy quality assurance

## Dose delivery particularities in ion therapy (I)

Effect of density changes in the target volume



Ions



Photons

Similar effects for mispositioning or organ movement

# 1. Imaging for hadron therapy quality assurance

## Dose delivery particularities in ion therapy (II)


The dose distribution deposited by ions is extremely sensitive to the ion range in vivo

The accuracy of the ion range is influenced by

(1) Systematic errors in the physical beam model used for treatment planning:  $R = R(HU)$

(2) Random errors like

- mispositioning
- patient- or organ movement
- density changes within the irradiated volume
- treatment mistakes and accidents



**Desirable:** A procedure for the verification

- of the irradiation field position
- of the particle range
- simultaneous with the therapeutic irradiation

and, in particular a procedure for the quantification of the dose distribution



- in-situ
- in-vivo
- in real time.

# 1. Imaging for hadron therapy quality assurance


## The physical dilemma

Dose deposition: electronic stopping of ions, i.e. atomic processes

$$-\left(\frac{dE_K}{dx}\right)_e = 2\pi N_A r_e^2 m_e c^2 \rho z^2 \frac{Z}{A} \frac{1}{\beta^2} \left[ \ln \frac{2m_e c^2 \beta^2 \gamma^2 T_{\max}}{I^2} - 2\beta^2 - \delta - 2\frac{C}{Z} \right]$$



Origin of highly penetrable signals: nuclear processes





# 1. Imaging for hadron therapy quality assurance

## The physical basis of PT-PET: Autoactivation

Peripheral nucleus-nucleus-collisions, nuclear reactions ( $^AZ, xp, yn$ ),  $\Delta p \approx 0$

$Z \geq 6$  Projectile fragments Target fragments

$Z < 6$  Target fragments



Therapy beam	$^1\text{H}$	$^3\text{He}$	$^7\text{Li}$	$^{12}\text{C}$	$^{16}\text{O}$	Nuclear medicine
Activity density / $\text{Bq cm}^{-3} \text{ Gy}^{-1}$	6600	5300	3060	1600	1030	$10^4 - 10^5 \text{ Bq cm}^{-3}$


W. Enghardt et al.: Phys. Med. Biol. 37 (1992) 2127;  
K. Parodi et al.: IEEE T. Nucl. Sci. 52 (2005) 778;  
F. Sommerer et al.: Phys. Med. Biol. 54 (2009) 3979;

J. Pawelke et al.: IEEE T. Nucl. Sci. 44 (1997) 1492;  
F. Fiedler et. al.: IEEE T. Nucl. Sci., 53 (2006) 2252;  
M. Priegnitz et al.: Phys. Med. Biol. 53 (2008) 4443




# 1. Imaging for hadron therapy quality assurance

In-beam, in-room, off-line










1<sup>st</sup> field  
0.66 Gy



2<sup>nd</sup> field  
0.37 Gy

Prescribed dose





# 1. Imaging for hadron therapy quality assurance

Installations: LBL

## In-beam PET

### PEBA II

- Double head ( $10 \times 10 \text{ cm}^2$ ) system
- $8 \times 8$  BGO crystals
- crystal size:  $1.25 \times 1.25 \times 3 \text{ cm}^3$






# 1. Imaging for hadron therapy quality assurance

Installations: HIMAC

In-beam PET



INSTITUTE OF PHYSICS PUBLISHING

PHYSICS IN MEDICINE AND BIOLOGY

Phys. Med. Biol. 48 (2003) 2269–2281

PII: S0031-9155(03)59468-4

**Washout measurement of radioisotope implanted by radioactive beams in the rabbit**

H Mizuno<sup>1,2</sup>, T Tomitani<sup>3</sup>, M Kanazawa<sup>3</sup>, A Kitagawa<sup>3</sup>, J Pawelke<sup>4</sup>,  
Y Iseki<sup>5</sup>, E Urakabe<sup>3</sup>, M Suda<sup>3</sup>, A Kawano<sup>3</sup>, R Iritani<sup>6</sup>, S Matsushita<sup>6</sup>,  
T Inaniwa<sup>7</sup>, T Nishio<sup>8</sup>, S Furukawa<sup>3</sup>, K Ando<sup>3</sup>, Y K Nakamura<sup>2</sup>,  
T Kanai<sup>6</sup> and K Ishii<sup>1</sup>



Y. Iseki et al NIM A 515 (2003) 840

# 1. Imaging for hadron therapy quality assurance

Installations: GSI

## In-beam PET

- Double head (42 × 21 cm<sup>2</sup>) system
- 64 × 32 BGO crystals
- crystal size: 6,75 × 6,75 × 30 mm<sup>3</sup>



# 1. Imaging for hadron therapy quality assurance

Installations: MGH

## Off-beam PET







# 1. Imaging for hadron therapy quality assurance

Installations: National Cancer Center, Kashiwa

In-room PET at a rotating beam delivery: Beam ON-LINE PET system



- Double head ( $12 \times 19 \text{ cm}^2$ ) system
- $40 \times 60$  BGO crystals
- crystal size:  $2 \times 2 \times 20 \text{ mm}^3$

- DAQ: 200 s after irradiation

# 1. Imaging for hadron therapy quality assurance

## Further installations

---

Hyogo Ion Beam Medical Center, Hyogo, Japan: [off-line](#)

CATANA, Catania, ocular beamline, Catania, Italy: [in-beam](#)


University of Florida Proton Therapy Institute, Jacksonville, USA: [off-line](#)



# 2. Lessons learned from particle therapy PET

## The clinical workflow


Ion-electron  
interaction



Treatment plan:  
dose-distribution


Chordoma, 0.5 Gy, 6 min

Monte Carlo:  
from the projectiles  
to the detection of  
annihilation  $\gamma$ -rays



$\beta^+$ -activity:  
prediction

Ion-nucleus  
interaction




$\beta^+$ -activity:  
measurement

W. Enghardt et al.:  
Strahlenther. Onkol. 175/II (1999) 33;  
F. Pönisch et al.:  
Phys. Med. Biol. 48 (2003) 2419,  
Phys. Med. Biol. 49 (2004) 5217;


# 2. Lessons learned from particle therapy PET

## The data processing



# 2. Lessons learned from particle therapy PET

The instrumentation (Example: in-beam PET)




## 2. Lessons learned from particle therapy PET

### Performance of PT-PET

- 😊 Particle range in vivo
- 😊 Lateral field position in vivo
- 😐 Patient positioning
- 😞 Semi-quantitative
- 😞 No direct dosimetry
- 😞 No real time capability
- 😞 Low signal-to-noise ratio

## 2. Lessons learned from particle therapy PET

### Particle range in vivo



Range verification by visual inspection:


$\Delta R = 6 \text{ mm}$ , *sensitivity* =  $(93 \pm 4) \%$ , *specificity* =  $(96 \pm 3) \%$

Automatisation in progress (ENVISION, WP5)



## 2. Lessons learned from particle therapy PET

### Patient positioning



# 2. Lessons learned from particle therapy PET

Semi-quantitative, no direct dosimetry

- Feasibility to solve the inverse problem:

$$\mathbf{A}(\mathbf{r}) = \mathbf{T} \mathbf{D}(\mathbf{r})$$

$\mathbf{A}(\mathbf{r})$

– spatial distribution of activity

$\mathbf{D}(\mathbf{r})$

– spatial distribution of dose


$\mathbf{T}$

– transition matrix

- Limited angle artefacts (in-beam PET)

- Quantification of metabolic washout rate of  $\beta^+$ -radioactivity impossible



- individual
- tissue dependent
- dose dependent
- fraction dependent
- disturbed by the tumour









## 2. Lessons learned from particle therapy PET

No direct dosimetry

Fraction  $x + 3$



Fraction  $x$




## 2. Lessons learned from particle therapy PET

### In-beam PET at cw-accelerators – cyclotrons (I)

Not realized, cf. BOLPs at Kashiwa: PET after irradiation

Part of the PET-countrate-time histogram of a therapeutic irradiation (GSI)



True coincidences from  $\beta^+$ -decay:  
used for reconstruction

Mainly random coincidences from  $\gamma$ -ray background  
during beam extraction: **rejected from reconstruction**




# 2. Lessons learned from particle therapy PET


## In-beam PET at cw-accelerators – cyclotrons (II)

The solution

Particle-RF  
time measurement






Veto during microbunch








# 3. Towards a real-time in-vivo dosimetry

## Direct TOF-PET (I)



dTOF-reconstruction,  
parameter  $\tau$  (FWHM)



# 3. Towards a real-time in-vivo dosimetry


## Direct in-beam TOF-PET (II)

- 😊 Particle range in vivo
- 😊 Lateral field position in vivo
- 😐 Patient positioning
- 😞 Semi-quantitative (metabolism)
- 😞 No direct dosimetry (metabolism)
- 😊 Real time capability
- 😞 Low signal-to-noise ratio (cross sections)

# 3. Towards a real-time in-vivo dosimetry


## Prompt reaction products – in-beam SPECT

GEANT 4



Balance of promptly emitted particles outside the target:


Incident protons:	1.0	( $\sim 10^{10}$ )
$\gamma$ -rays:	0.3	( $3 \cdot 10^9$ )
Neutrons:	0.09	( $9 \cdot 10^8$ )
Protons:	0.001	( $1 \cdot 10^7$ )
$\alpha$ -particles:	$2 \cdot 10^{-5}$	( $2 \cdot 10^5$ )



Requirement: Neutron blind, high spatial resolution  $\gamma$ -camera of wide energy acceptance

# 3. Towards a real-time in-vivo dosimetry

## Detectors for in-beam SPECT: Compton cameras (I)



Kinematics of incoherent scattering:

$$\cos \varphi = 1 - m_0 c^2 \left( \frac{1}{E_{\gamma'}} - \frac{1}{E_{\gamma}} \right)$$

$$E_{\gamma} = E_{e^-} + E_{\gamma'}$$

Sensitivity:

$$\eta_{CC} \approx 100 \eta_{AC}$$

S. Chelikani et al.:


Phys. Med. Biol. 49 (2004) 1387

Problems:

- Continuous  $\gamma$ -ray spectra
- $E_{\gamma}$  unknown
- $\gamma'$  must be completely absorbed

# 3. Towards a real-time in-vivo dosimetry

## Detectors for in-beam SPECT: Compton cameras (II)



$$\cos \varphi_1 = 1 - m_0 c^2 \left( \frac{1}{E_2} - \frac{1}{E_1} \right)$$

$$\cos \varphi_2 = 1 - m_0 c^2 \left( \frac{1}{E_3} - \frac{1}{E_2} \right)$$

$$E_{e^-}^{(1)} = E_1 - E_2$$

$$E_{e^-}^{(2)} = E_2 - E_3$$

Known:  $\varphi_2, E_{e^-}^{(1)}, E_{e^-}^{(2)}$


Unknown:  $\varphi_1, E_1, E_2, E_3$

- Efficiency: 25 – 50 % for  $E_1 > 1$  MeV
- No absorption necessary
- No high  $Z$  absorber required




### 3. Towards a real-time in-vivo dosimetry


Detectors for in-beam SPECT: Compton cameras (III)




(a) 2 Events




(b) 3 Events




(c) 10 Events



(d) 20 Events



(e) 100 Events




(f) 300 Events

### 3. Towards a real-time in-vivo dosimetry

#### Detectors for in-beam SPECT: Compton cameras (IV)

Tomographic reconstruction



(c) 100 Events, nach Iteration 1, 2, 3 und 10